DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

RCT of ACP for Transplant

Withdrawn

Conditions: Cancer Patients Undergoing Stem Cell Transplantation (RCT of ACP for Transplant)

Interventions: Other: Surveys

First Posted Date: 2017-05-18

Last Posted Date: 2018-09-20

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT03158467

A PHASE I, SINGLE-CENTER, MIXED METHODS STUDY ON THE HEALTH OUTCOMES OF VISUAL SELF EXPRESSION

Completed

Conditions: A Healthcare Professional, a Patient or Caregiver in the Radiation Oncology Department at the University of Pennsylvania

First Posted Date: 2017-05-16

Last Posted Date: 2020-04-15

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 80

Registration Number: NCT03155672

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A PILOT STUDY OF DIFFUSION WEIGHTED MRI TO ASSESS ESOPHAGEAL TUMOR RESONSE TO NEOADJUVANT CHEMORADIATION

Completed

Conditions: Esophageal Cancer

First Posted Date: 2017-05-12

Last Posted Date: 2021-04-26

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 11

Registration Number: NCT03151642

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

Phase 2

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: RUCAPARIB

First Posted Date: 2017-05-04

Last Posted Date: 2023-09-28

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 46

Registration Number: NCT03140670

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pembrolizumab

First Posted Date: 2017-03-22

Last Posted Date: 2024-01-18

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 32

Registration Number: NCT03087760

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: [18F]FluorThanatrace

First Posted Date: 2017-03-20

Last Posted Date: 2024-08-27

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 30

Registration Number: NCT03083288

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide

Terminated

Conditions: Non-Hodgkin Lymphoma

First Posted Date: 2017-02-28

Last Posted Date: 2021-06-04

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 1

Registration Number: NCT03065790

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer

Terminated

Conditions: METASTATIC BREAST CANCER

First Posted Date: 2017-02-20

Last Posted Date: 2021-11-18

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 4

Registration Number: NCT03057743

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer

Completed

Conditions: Lung Cancer

First Posted Date: 2017-02-09

Last Posted Date: 2021-04-19

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 88

Registration Number: NCT03047616

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

Phase 2

Active, not recruiting

Conditions: Breast Cancer Stage IIB

Interventions: Drug: Hydroxychloroquine
Drug: Everolimus

First Posted Date: 2017-01-26

Last Posted Date: 2025-03-05

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 53

Registration Number: NCT03032406

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy